YOLFTbeta
Adicet Bio Inc

Adicet Bio Inc

ACET · NASDAQ · Healthcare / Biotechnology

2.78USD-0.15 (-5.12%)

Price History

Full chart

Market Stats

Previous Close2.93
Open2.92
Day Range2.73 – 2.98
52-Week Range6.01 – 17.44
Volume286.38K
Market Cap84.44M
P/E (TTM)0.00
Forward P/E0.00
EPS-10.42
Dividend Yield0.00%
Beta1.59
50-Day Avg8.81
200-Day Avg8.05

About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Chen Schor BA, CPA, M.B.A.
  • Employees102
  • Headquarters131 Dartmouth Street, Boston, MA, United States, 02116, USA
  • Websitehttps://www.adicetbio.com

Leadership

  • Mr. Chen Schor BA, CPA, M.B.A.CEO, President & Director · b. 1972
  • Dr. Blake Aftab Ph.D.Senior VP & Chief Scientific Officer · b. 1981
  • Dr. Lloyd Klickstein M.D., Ph.D.Interim Chief Medical Officer & Director · b. 1957
  • Mr. Brian Nicholas Harvey M.B.A.Chief Financial Officer · b. 1961
  • Dr. Donald Healey Ph.D.Chief Technology Officer · b. 1962
  • Ms. Amy LockeChief Human Resource Officer

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue359.59M322.65M346.63M412.43M444.39M499.69M499.69M510.18M546.95M558.52M8.18M995.00K17.90M9.73M24.99M000
Growth (%)--10.27%+7.43%+18.98%+7.75%+12.44%0.00%+2.10%+7.21%+2.12%-98.54%-87.84%+1699.30%-45.65%+156.83%-100.00%--
Cost of Revenue292.29M267.03M292.48M346.59M362.36M401.42M401.42M395.48M411.52M5.00K80.00K125.00K--5.01M6.10M6.47M6.38M
Gross Profit67.31M55.62M54.16M65.84M82.03M98.27M98.27M114.70M135.43M558.52M8.10M995.00K17.90M9.73M24.99M-6.10M-6.47M-6.38M
Gross Margin18.72%17.24%15.62%15.96%18.46%19.67%19.67%22.48%24.76%100.00%99.02%100.00%100.00%100.00%100.00%---
Operating Expense45.93M43.73M44.72M49.29M56.67M63.85M63.85M70.43M135.44M577.40M23.07M32.38M57.09M71.16M97.54M145.94M121.15M115.73M
Operating Income21.38M11.89M9.44M16.55M25.37M34.42M34.42M44.27M-1.00K-18.88M-14.96M-31.39M-39.19M-61.43M-72.55M-152.04M-127.61M-122.11M
Operating Margin5.94%3.69%2.72%4.01%5.71%6.89%6.89%8.68%-0.00%-3.38%-182.91%-3154.57%-218.91%-631.38%-290.32%---
EBITDA24.71M14.70M13.23M24.03M34.31M43.62M43.62M54.87M-1.00K-33.77M-13.74M-26.88M-37.41M-60.41M-64.70M-136.53M-110.65M-110.39M
EBITDA Margin6.87%4.55%3.82%5.83%7.72%8.73%8.73%10.75%-0.00%-6.05%-167.97%-2701.61%-208.95%-620.86%-258.91%---
Net Income13.47M8.63M6.58M8.97M16.98M22.33M22.33M29.00M-1.00K-33.78M-9.30M-28.14M-36.68M-62.00M-69.79M-142.66M-117.12M-116.80M
Net Income Margin3.75%2.67%1.90%2.17%3.82%4.47%4.47%5.68%-0.00%-6.05%-113.67%-2827.94%-204.87%-637.19%-279.27%---
R&D506.00K153.00K----2.83M5.22M5.94M16.84M14.72M23.69M34.33M48.94M71.25M106.04M99.32M99.13M
R&D as % of Total Revenue0.14%0.05%----0.57%1.02%1.09%3.01%179.89%2381.01%191.78%503.01%285.10%---
Interest Expense145.00K98.00K230.00K1.57M2.63M2.12M2.12M2.10M3.95M7.00M--134.00K176.00K80.00K25.00K4.00K36.00K
Interest Expense % of Total Revenue0.04%0.03%0.07%0.38%0.59%0.42%0.42%0.41%0.72%1.25%--0.75%1.81%0.32%---

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets205.50M189.27M216.56M294.99M299.28M323.43M467.98M489.77M540.78M55.19M109.94M81.59M153.84M338.94M330.69M207.29M220.22M192.35M
Total Liabilities81.83M63.90M92.21M150.84M131.28M128.79M234.40M235.56M236.34M5.50M5.74M141.95M44.01M35.81M38.35M37.12M33.61M33.15M
Total Equity140.41M141.57M139.64M160.82M168.00M194.64M233.58M254.21M304.44M49.69M104.20M-60.37M109.83M303.13M292.34M170.18M186.61M159.21M
Cash46.52M57.76M30.85M28.66M24.86M33.23M42.90M34.02M66.83M53.35M7.04M10.61M84.33M277.54M257.66M159.71M56.49M38.92M
Total Debt19.95M20.74M33.59M55.00M45.77M32.07M105.50M110.16M118.79M353.67M3.11M114.08M21.64M20.94M21.02M20.92M17.23M14.74M
Net Debt-26.57M-37.02M2.74M26.33M20.90M-1.16M62.60M76.14M51.96M300.32M-3.93M-10.61M-62.69M-256.60M-236.63M-138.79M-39.26M-24.18M

Cash Flow

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow15.42M22.51M-15.50M14.04M13.27M23.73M25.48M25.06M8.34M-11.55M-18.18M-27.88M-41.55M-51.05M-44.77M-93.72M-92.38M-95.25M
Investing Cash Flow1.40M-4.06M-6.11M-69.20M-1.78M-1.06M-2.80M-85.92M-8.97M-44.00K-16.06M-47.93M115.22M-2.80M-16.78M-4.46M-119.24M2.39M
Financing Cash Flow-6.03M-4.26M-2.44M49.97M-15.29M-14.31M-14.31M70.53M-8.24M64.95M11.05M76.94M303.00K242.69M41.51M236.00K111.31M75.25M
Capital Expenditure1.20M557.00K3.96M5.42M1.10M1.02M1.02M1.15M617.00K44.00K876.00K1.07M990.00K13.05M16.78M4.46M1.12M1.74M
Free Cash Flow14.22M21.95M-19.46M8.61M12.17M22.71M24.45M23.91M7.73M-11.60M-19.06M-28.95M-42.54M-64.10M-61.55M-98.18M-93.50M-96.98M
Dividends Paid-4.95M5.07M5.21M5.33M6.02M6.02M6.81M6.96M7.08M--------
FCF to OCF92.24%97.53%125.55%61.35%91.73%95.69%95.99%95.43%92.60%100.38%104.82%103.84%102.38%125.55%137.49%104.76%101.21%101.82%
Dividend Paid to FCF-22.54%-26.04%60.44%43.80%26.49%24.60%28.46%90.14%-61.08%--------

Earnings

Report DateJun 30, 2016Sep 30, 2016Feb 3, 2017May 4, 2017Aug 24, 2017Nov 29, 2017Mar 29, 2018May 10, 2018Aug 9, 2018Nov 13, 2018Mar 18, 2019May 15, 2019Aug 14, 2019Nov 5, 2019Mar 12, 2020May 7, 2020Jul 30, 2020Nov 5, 2020Mar 11, 2021May 17, 2021Aug 12, 2021Nov 10, 2021Mar 15, 2022May 12, 2022Aug 10, 2022Nov 8, 2022Mar 15, 2023May 9, 2023Aug 9, 2023Nov 8, 2023Mar 19, 2024May 14, 2024Aug 13, 2024Nov 6, 2024Mar 17, 2025May 6, 2025Aug 7, 2025Nov 5, 2025Mar 5, 2026May 13, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.390.290.300.440.440.29-7.21-1.71-2.94-3.53-2.38-2.52-2.74-3.76-4.39-2.36-1.74-12.32-13.36-0.49-8.45-6.82-0.42-6.08-7.47-8.49-0.28-10.53-6.81-12.00-0.69-6.28-5.84-5.33-0.35-5.38-0.32-0.26-0.19-3.08-2.43-1.56
EPS Actual0.350.28-0.12-0.120.27-9.10-35.77-3.22-3.36-2.10-1.47-2.66-3.57-4.76-5.53-1.33-1.05-12.00-7.36-0.82-5.44-7.04-0.471.60-8.96-8.48-0.72-11.52-12.00-18.56-0.69-5.60-5.28-5.44-0.32-4.96-0.34-0.29-2.94-1.88-1.99-
Surprise-10.26%-3.45%-140.00%-127.27%-38.64%-3237.93%-396.12%-88.30%-14.29%40.51%38.24%-5.56%-30.29%-26.60%-25.97%43.64%39.66%2.60%44.91%-67.35%35.62%-3.23%-11.90%126.32%-19.95%0.12%-157.14%-9.40%-76.21%-54.67%0.00%10.83%9.59%-2.06%9.86%7.81%-6.25%-11.54%-1422.53%38.96%18.11%-
Timing------After-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap84.44M
Enterprise Value-26.42M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.82
Price / Sales9.72
Price / Book0.66
EPS-10.42
Book Value11.16
Revenue (TTM)0
Gross Profit (TTM)24.99M
EBITDA-98.12M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-78.08%
Return on Assets-41.67%
Shares Outstanding9.36M
Shares Float7.44M
Beta1.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 33.17
  • Strong Buy
    6
  • Hold
    1

Ownership Breakdown

Institutions
64.70%
Insiders
1.08%
Retail / Other
34.22%

Top Institutional Holders

  • RA Capital Management, LLC
    1.18M12.63%
  • Orbimed Advisors LLC
    1.03M10.98%
  • Franklin Templeton Inc
    626.57K6.69%
  • Citadel Advisors Llc
    432.74K4.62%
  • Vanguard Capital Management, LLC
    336.52K3.59%
  • Woodline Partners LP
    313.12K3.34%
  • Adage Capital Partners Gp LLC
    274.38K2.93%
  • Renaissance Technologies Corp
    232.59K2.48%
  • Stonepine Capital Management Llc
    221.96K2.37%
  • Alyeska Investment Group, L.P.
    203.80K2.18%
  • The Carlyle Group Inc
    184.29K1.97%
  • NEXTBio Capital Management LP
    157.83K1.69%
  • Acadian Asset Management LLC
    118.14K1.26%
  • Geode Capital Management, LLC
    101.14K1.08%
  • Two Sigma Investments LLC
    96.84K1.03%
  • Dafna Capital Management LLC
    93.81K1.00%

Top Fund Holders

  • Franklin Biotechnology Discv A(acc)USD
    401.35K4.29%
  • Vanguard MStar Total Stk Mkt Idx Invest
    243.23K2.60%
  • Franklin Biotechnology Discovery A
    225.19K2.41%
  • Bridgeway Ultra-Small Company
    85.96K0.92%

Dividends

20183×
0.01Sep 21, 20180.01Jun 7, 20180.07Mar 8, 2018

Stock Splits

  • Dec 30, 20251:16
  • Sep 16, 20201:7